體重較重病患更適合以letrozole誘導排卵

體重較重之病患可能更適合以letrozole誘導排卵
(pregnancy 10.4% and 18.2% of BMI <30 and BMI ≥30)

http://www.ncbi.nlm.nih.gov/pubmed/21867999

Fertil Steril. 2011 Nov;96(5):1206-8. doi: 10.1016/j.fertnstert.2011.08.002. Epub 2011 Aug 24.

Body mass index-associated differences in response to ovulation induction with letrozole.

McKnight KK, Nodler JL, Cooper JJ Jr, Chapman VR, Cliver SP, Bates GW Jr.

Source

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Alabama, Birmingham, Alabama, USA. kkmcknight@gmail.com

Abstract

OBJECTIVE:

To compare occurrence of pregnancy among obese (body mass index [BMI] ≥30) and nonobese (BMI <30), infertile women undergoing ovulation induction with the aromatase inhibitor letrozole followed by intrauterine insemination (IUI).

DESIGN:

Retrospective cohort study.

SETTING:

Academic reproductive endocrinology and infertility clinic.

PATIENT(S):

Ninety women with a variety of infertility diagnoses.

INTERVENTION(S):

Letrozole (5 mg) on menstrual cycle days 3-7, followed by intrauterine insemination (IUI).

MAIN OUTCOME MEASURE(S):

Occurrence of pregnancy and pregnancy outcomes.

RESULT(S):

Ninety women underwent 180 letrozole-IUI cycles. Conception of pregnancy occurred in 10.4% and 18.2% of the BMI <30 and BMI ≥30 groups, respectively. Using BMI as a continuous variable showed a pregnancy odds ratio of 1.093 (confidence interval 1.008-1.184) for each unit increase in BMI. Incidence of miscarriage, multiple births, number of mature follicles, and presence of LH surge were similar between groups.

CONCLUSION(S):

Our study of 90 women undergoing letrozole-IUI treatment showed greater likelihood of pregnancy in higher-BMI women, although the difference was not significant. Letrozole is an effective ovulation induction agent in higher-BMI women.